Cardiovascular sequelae of breast cancer treatments: A review
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Current Problems in Cancer
- Vol. 42 (4) , 409-421
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Anthracycline-Induced CardiomyopathyJACC, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005